Celyad Oncology SA (CYAD)

NASDAQ: CYAD · IEX Real-Time Price · USD
3.85
-0.14 (-3.51%)
At close: Jan 14, 2022 4:00 PM
3.82
-0.03 (-0.78%)
After-hours:Jan 14, 2022 4:00 PM EST
Market Cap89.82M
Revenue (ttm)n/a
Net Income (ttm)-18.41M
Shares Out23.33M
EPS (ttm)-1.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,761
Open3.90
Previous Close3.99
Day's Range3.82 - 3.99
52-Week Range3.53 - 9.00
Beta1.32
AnalystsStrong Buy
Price Target19.00 (+393.5%)
Earnings Daten/a

About CYAD

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T thera...

IndustryBiotechnology
Founded2004
CEOFilippo Petti
Employees87
Stock ExchangeNASDAQ
Ticker SymbolCYAD
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for CYAD stock is "Strong Buy." The 12-month stock price forecast is 19.00, which is an increase of 393.51% from the latest price.

Price Target
$19.00
(393.51% upside)
Analyst Consensus: Strong Buy

News

Celyad Oncology Provides Outlook for 2022

MONT-SAINT-GUIBERT, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

6 days ago - GlobeNewsWire

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols:APTOCELUCNSPSPRB
2 weeks ago - Zacks Investment Research

Celyad Oncology Announces January 2022 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

3 weeks ago - GlobeNewsWire

Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

4 weeks ago - GlobeNewsWire

Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and developme...

1 month ago - GlobeNewsWire

Transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

1 month ago - GlobeNewsWire

Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

1 month ago - Business Wire

Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate

MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the discovery a...

1 month ago - GlobeNewsWire

How to Make Money With Penny Stocks And the Omicron Variant

Trading penny stocks right now? Consider these three tips and tricks The post How to Make Money With Penny Stocks And the Omicron Variant appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols:BIOLPTPITOMZ
1 month ago - PennyStocks

Hot Biotech Stocks: Why Celyad Oncology (CYAD) Is Soaring Higher Today

Celyad Oncology (CYAD) stock is heading higher on Friday following the announcement of a $32.5 million private placement. The post Hot Biotech Stocks: Why Celyad Oncology (CYAD) Is Soaring Higher Today ...

1 month ago - InvestorPlace

Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

MONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the discovery a...

1 month ago - GlobeNewsWire

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Expos...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

2 months ago - Business Wire

Celyad Oncology Announces November 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

2 months ago - GlobeNewsWire

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer An...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

3 months ago - Business Wire

Celyad Oncology Announces September 2021 Conferences Schedule

MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ...

4 months ago - GlobeNewsWire

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developme...

5 months ago - GlobeNewsWire

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on ...

5 months ago - Business Wire

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Rese...

MONT-SAINT-GUIBERT, Belgium, July 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad Oncology or the Company), a clinical-stage biotechnology company focused on the discov...

5 months ago - GlobeNewsWire

Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

6 months ago - Business Wire

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYA...

MONT-SAINT-GUIBERT, Belgium, June 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric a...

7 months ago - GlobeNewsWire

Celyad Oncology Announces June 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on ...

7 months ago - Business Wire

Transparency notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, May 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

7 months ago - GlobeNewsWire

Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

Celyad Oncology SA (NASDAQ: CYAD) has announced initial clinical data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in patients with relapsed or refractory multiple myeloma. The data will be pre...

8 months ago - Benzinga

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 ...

MONT-SAINT-GUIBERT, Belgium, May 12, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric an...

8 months ago - GlobeNewsWire

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 06, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and developmen...

8 months ago - GlobeNewsWire